Table 4.
Altered Pathways by Deregulated miR in Endometrial Cancer.
| A. KEGG Pathways Regulated by Upregulated miR | ||||
|---|---|---|---|---|
| S. No. | Name | Hits | p-Value | Adj. p-Value |
| 1 | Pathways in cancer | 9 | 3.27 × 10−08 | 1.3407 × 10−06 |
| 2 | Prostate cancer | 5 | 0.00000347 | 0.000071135 |
| 3 | Glioma | 4 | 0.0000306 | 0.00037515 |
| 4 | p53 signaling pathway | 4 | 0.0000366 | 0.00037515 |
| 5 | Melanoma | 3 | 0.000952 | 0.006792333 |
| 6 | Pancreatic cancer | 3 | 0.000994 | 0.006792333 |
| 7 | Small cell lung cancer | 3 | 0.00153 | 0.008961429 |
| 8 | Focal adhesion | 4 | 0.00231 | 0.01183875 |
| 9 | Bladder cancer | 2 | 0.00322 | 0.01466889 |
| 10 | mTOR signaling pathway | 2 | 0.00765 | 0.031365 |
| B. Gene Ontology Enrichment for Biological Process (GO-BP) Regulated by Upregulated miR | ||||
| S. No. | Name | Hits | p-Value | Adj. p-Value |
| 1 | negative regulation of apoptotic process | 12 | 1.01 × 10−10 | 4.10 × 10−09 |
| 2 | negative regulation of programmed cell death | 12 | 1.01 × 10−10 | 4.10 × 10−09 |
| 3 | regulation of gene expression | 12 | 1.23 × 10−10 | 4.10 × 10−09 |
| 4 | apoptotic process | 21 | 3.23 × 10−09 | 8.05 × 10−08 |
| 5 | programmed cell death | 16 | 4.83 × 10−09 | 8.05 × 10−08 |
| 6 | regulation of apoptotic process | 16 | 4.83 × 10−09 | 8.05 × 10−08 |
| 7 | regulation of programmed cell death | 16 | 5.83 × 10−09 | 8.33 × 10−08 |
| 8 | cell proliferation | 14 | 8.25 × 10−09 | 1.03 × 10−07 |
| 9 | regulation of RNA metabolic process | 14 | 9.61 × 10−09 | 1.07 × 10−07 |
| 10 | regulation of nucleobase-containing compound metabolic process | 15 | 1.20 × 10−08 | 1.20 × 10−07 |
| C. Gene Ontology Enrichment for Molecular Function (GO-MF) Regulated by Upregulated miR | ||||
| S. No. | Name | Hits | p-Value | Adj. p-Value |
| 1 | negative regulation of transcription, DNA-dependent | 10 | 0.00000168 | 0.00016128 |
| 2 | transcription from RNA polymerase II promoter | 12 | 0.0000173 | 0.0008304 |
| 3 | protein kinase binding | 5 | 0.000325 | 0.0101376 |
| 4 | enzyme binding | 8 | 0.000476 | 0.0101376 |
| 5 | kinase binding | 5 | 0.000528 | 0.0101376 |
| 6 | RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor activity | 3 | 0.000768 | 0.012288 |
| 7 | sequence-specific DNA binding | 6 | 0.001 | 0.01365333 |
| 8 | ubiquitin-protein ligase activity | 4 | 0.00124 | 0.01365333 |
| 9 | transcription factor binding | 5 | 0.00128 | 0.01365333 |
| 10 | small conjugating protein ligase activity | 4 | 0.00162 | 0.01413818 |
| D. KEGG Pathways Regulated by Downregulated miR | ||||
| S. No. | Name | Hits | p-Value | Adj. p-Value |
| 1 | Chronic myeloid leukemia | 11 | 9.87 × 10−12 | 9.57 × 10−10 |
| 2 | Pathways in cancer | 17 | 1.30 × 10−10 | 6.31 × 10−09 |
| 3 | Colorectal cancer | 8 | 4.76 × 10−09 | 1.54 × 10−07 |
| 4 | Glioma | 8 | 4.83 × 10−08 | 1.17 × 10−06 |
| 5 | Melanoma | 8 | 6.94 × 10−08 | 0.000001261 |
| 6 | Pancreatic cancer | 8 | 7.80 × 10−08 | 0.000001261 |
| 7 | Prostate cancer | 8 | 4.88 × 10−07 | 6.22 × 10−06 |
| 8 | Focal adhesion | 11 | 5.13 × 10−07 | 6.22 × 10−06 |
| 9 | Thyroid cancer | 5 | 0.000003 | 3.23 × 10−05 |
| 10 | ErbB signaling pathway | 7 | 0.00000682 | 0.000066154 |
| E. Gene Ontology Enrichment for Biological Process (GO-BP) Regulated by Downregulated miR | ||||
| S. No. | Name | Hits | p-Value | Adj. p-Value |
| 1 | regulation of cell proliferation | 27 | 5.61 × 10−07 | 0.000023725 |
| 2 | positive regulation of metabolic process | 39 | 8.03 × 10−07 | 0.000023725 |
| 3 | regulation of cellular protein metabolic process | 28 | 9.08 × 10−07 | 0.000023725 |
| 4 | gland development | 12 | 9.49 × 10−07 | 0.000023725 |
| 5 | tissue morphogenesis | 16 | 0.0000012 | 0.000024 |
| 6 | morphogenesis of an epithelium | 14 | 0.00000152 | 2.444 × 10−05 |
| 7 | negative regulation of cell proliferation | 16 | 0.00000185 | 2.444 × 10−05 |
| 8 | negative regulation of metabolic process | 30 | 0.00000206 | 2.444 × 10−05 |
| 9 | regulation of kinase activity | 18 | 0.0000022 | 2.444 × 10−05 |
| 10 | enzyme linked receptor protein signaling pathway | 23 | 0.00000271 | 2.692 × 10−05 |
| F. Gene Ontology Enrichment for Molecular Function (GO-MF) Regulated by Downregulated miR | ||||
| S. No. | Name | Hits | p-Value | Adj. p-Value |
| 1 | protein complex binding | 10 | 0.0000896 | 0.00896 |
| 2 | transcription from RNA polymerase II promoter | 25 | 0.000725 | 0.02716667 |
| 3 | negative regulation of transcription, DNA-dependent | 16 | 0.000815 | 0.02716667 |
| 4 | SMAD binding | 4 | 0.00111 | 0.02775 |
| 5 | kinase binding | 9 | 0.00194 | 0.0388 |
| 6 | protein kinase binding | 8 | 0.00372 | 0.062 |
| 7 | SH3/SH2 adaptor activity | 3 | 0.00508 | 0.07257143 |
| 8 | transcription factor binding | 9 | 0.00705 | 0.085 |
| 9 | phosphatase binding | 4 | 0.00765 | 0.085 |
| 10 | cytokine receptor binding | 6 | 0.00892 | 0.0892 |
Pathway enrichment analysis for deregulated miR in endometrial cancer: Gene targets for miR were predicted using the miRNet web tool (https://www.mirnet.ca/) and miRTarBase v8.0. (A,D) KEGG pathway analysis enrichment, gene ontology enrichment for (B,E) biological process (GO-BP) and (C,F) molecular function (GO-MF) were analyzed for upregulated (A–C) and downregulated (D–F) miR target genes, the 10 most significant pathways based on the network generated using degree cutoff 5 are shown.